FDA DRUG INSPECTION INITIATIVES
This article was originally published in The Gold Sheet
Executive Summary
...include a new pilot program involving pre-announced inspections, annotated FD-483s, and notification of positive audit results. After success with these innovations in the medical device area, field management will test them for drugs beginning in 1999 in an effort to improve FDA/ industry communications. FDA is moving forward with other initiatives to reshape and streamline its drug and biologic inspection programs, including: § § an MRA with the EU § § an internationally harmonized bulk GMP guideline § § guidance on out-of-specification result investigations § § Team Biologics § § investigator certification § § a first party audit program, and § § an effort to focus firms on the year 2000 computer problem.
You may also be interested in...
McKinsey Survey Highlights Progress, Challenges in Adoption of QbD
Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.
Manufacturers Encouraged to Enhance Clinical Relevance of Quality With QbD
Using QbD to set specs that make a difference to patients is hard but important work, FDA's Woodcock says. Prasugrel, levothyroxine, pallodone examples explored. How to establish a 'work space.' How to make the right correlations.
Biotech QbD Encounters Uncertainties Over Definitions and Regulatory Relief
As biotech firms begin to pilot QbD they wrestle with FDA over non-critical process parameters, postapproval changes and more. They are exploring how to define design spaces, change them, identify their edges. And they're still wondering what regulatory relief they might get in return for investing in quality-by-design studies.